Evidence map›Paper›PMID 35440446›Full record

ArticleBMJ open2022

Protocol for the COG-UK hospital-onset COVID-19 infection (HOCI) multicentre interventional clinical study: evaluating the efficacy of rapid genome sequencing of SARS-CoV-2 in limiting the spread of COVID-19 in UK NHS hospitals.

James Blackstone, Oliver Stirrup, Fiona Mapp, Monica Panca, Andrew Copas, Paul Flowers, Leanne Hockey, James Price, David Partridge, Christine Peters and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

James BlackstoneComprehensive Clinical Trials Unit, University College London, London, UK.ORCID 0000-0003-4335-5269
Oliver StirrupInstitute for Global Health, University College London, London, UK.
Fiona MappInstitute for Global Health, University College London, London, UK.ORCID 0000-0003-0733-6036
Monica PancaComprehensive Clinical Trials Unit, University College London, London, UK.
Andrew CopasInstitute for Global Health, University College London, London, UK.ORCID 0000-0001-8968-5963
Paul FlowersSchool of Psychology & Health, University of Strathclyde, Glasgow, UK.ORCID 0000-0001-6239-5616
Leanne HockeyComprehensive Clinical Trials Unit, University College London, London, UK.ORCID 0000-0001-5716-7643
James PriceDepartment of Infectious Disease, Imperial College London, London, UK.
David PartridgeDepartment of Virology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0002-0417-2016
Christine PetersQueen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
Thushan de SilvaDepartment of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.ORCID 0000-0002-6498-9212
Gaia NebbiaDepartment of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.ORCID 0000-0002-7524-1947
Luke B SnellDepartment of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.ORCID 0000-0002-6263-9497
Rachel McComishComprehensive Clinical Trials Unit, University College London, London, UK.
COVID-19 Genomics UK (COG-UK) Consortium
Judith BreuerInstitute of Child Health, University College London, London, UK j.breuer@ucl.ac.uk.
Comprehensive Clinical Trials · USUniversity College London · GBGuy's and St Thomas' NHS Foundation Trust · GBImmunité et Cancer · FRImperial College London · GBNHS Greater Glasgow and Clyde · GBSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity of Strathclyde · GB

Funding

Department of HealthMedical Research Council MC_PC_19027Medical Research Council MR/T005416/1
6 · The paper itself

Abstract

objectivesNosocomial transmission of SARS-CoV-2 has been a significant cause of mortality in National Health Service (NHS) hospitals during the COVID-19 pandemic. The COG-UK Consortium Hospital-Onset COVID-19 Infections (COG-UK HOCI) study aims to evaluate whether the use of rapid whole-genome sequencing of SARS-CoV-2, supported by a novel probabilistic reporting methodology, can inform infection prevention and control (IPC) practice within NHS hospital settings.

designMulticentre, prospective, interventional, superiority study.

setting14 participating NHS hospitals over winter-spring 2020/2021 in the UK.

participantsEligible patients must be admitted to hospital with first-confirmed SARS-CoV-2 PCR-positive test result >48 hour from time of admission, where COVID-19 diagnosis not suspected on admission. The projected sample size is 2380 patients.

interventionThe intervention is the return of a sequence report, within 48 hours in one phase (rapid local lab processing) and within 5-10 days in a second phase (mimicking central lab), comparing the viral genome from an eligible study participant with others within and outside the hospital site. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcomes are incidence of Public Health England (PHE)/IPC-defined SARS-CoV-2 hospital-acquired infection during the baseline and two interventional phases, and proportion of hospital-onset cases with genomic evidence of transmission linkage following implementation of the intervention where such linkage was not suspected by initial IPC investigation. Secondary outcomes include incidence of hospital outbreaks, with and without sequencing data; actual and desirable changes to IPC actions; periods of healthcare worker (HCW) absence. Health economic analysis will be conducted to determine cost benefit of the intervention. A process evaluation using qualitative interviews with HCWs will be conducted alongside the study. TRIAL REGISTRATION NUMBER: ISRCTN50212645. Pre-results stage. This manuscript is based on protocol V.6.0. 2 September 2021.

Indexed as

COVID-19Cross InfectionCOVID-19 TestingHospitalsHumansMulticenter Studies as TopicPandemicsProspective StudiesSARS-CoV-2State MedicineTreatment OutcomeUnited KingdomCOVID-19epidemiologyinfection controlmolecular biology

Identifiers

PMID35440446
PMCPMC9019828
OpenAlexW4224233399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.